Vision
Goodbye. Diabetes.
Towards the development of a treatment that completely cures diabetes.
The goal is to completely cure the disease, not just treat it symptomatically.
![](https://biozipcode.com/wp-content/uploads/2023/12/profile_Fumihisa_Kojima.webp)
Greetings from the Chief Executive Officer
Our company, Biozipcode, Inc., is tackling diseases that have yet to be overcome, starting with diabetes. Our mission is to provide fundamental treatments, not just to alleviate symptoms. Toward this goal, we utilize cutting-edge scientific and technological advancements to delve into the essence of diseases.
Our research extends beyond the development of pharmaceuticals; it aims to improve the quality of life for each individual patient. To achieve the complete cure of diabetes, scientific discoveries alone are not enough; societal understanding and support are essential. Therefore, we place great emphasis on collaboration with healthcare professionals, researchers, and most importantly, the patients and their families.
Our efforts signify more than just treating a single disease. They represent a step towards changing the future of healthcare and building a better society. By confronting each disease, we believe we can expand the possibilities of medical care and offer new hope to patients.
Today, Biozipcode, Inc. continues to strive not only for the development of a cure for diabetes but also for new challenges that contribute to the future of healthcare. We sincerely hope that our efforts will soon have a direct impact on the health and happiness of patients. And we look forward to our endeavors becoming a beacon of hope in the fight against diseases for people all over the world.
Biozipcode, Inc.
Fumihisa Kojima
Biozipcode, Inc.
Company Name | Biozipcode, Inc. |
Established | January 2022 (Reiwa 4th year) |
Capital | 70 million yen |
Head Office Location | Otsu, Shiga, Tsukinowa-cho, Shiga University of Medical Science Biomedical Innovation Facility |
Representative | President and CEO Fumihisa Kojima |
Advisors | Professor Hidehito Kojima, Shiga University of Medical Science Atsushi Kumada, Former Member of the House of Representatives |
Main Business | 1. Research, development, and sales of pharmaceuticals, including diabetes treatment drugs. 2. Research and development of technologies for delivering drugs and other substances to specific cells based on cell-related databases. 3. Contract development of systems and data analysis utilizing technology mentioned in 2. 4. Research, development, and sales of pesticides and insecticides that do not cause environmental pollution, targeting non-human animals and plants, utilizing technology mentioned in 2. 5. Licensing and sales of patent rights and other rights related to the above. 6. All businesses incidental to the above. |
![](https://biozipcode.com/wp-content/uploads/2022/10/otsukarahashi.jpg)
Karahashi Bridge in Seta, Otsu City
![](https://biozipcode.com/wp-content/uploads/2022/10/askdoc.jpg)
About therapeutic drugs that completely cure diabetes
![](https://biozipcode.com/wp-content/uploads/2022/10/topimage.jpg)
About Biozipcode (Cell Targeting Technology)
About the company logo
The symbol mark is an image of connecting “DNA” and guiding the way. Zipcode’s Z symbol is imagined as a DNA spiral, representing new adventures and challenges.
The typography uses his NotoSans, a new-age, universal typography, and uses bold fonts to show strength.
Light blue and blue gradation express the brightness of trust and hope.
![](https://biozipcode.com/wp-content/uploads/2023/12/logo.jpg)
FAQ
FAQ
We will answer frequently asked questions regarding BioZipcord’s business. If you have any questions that are not listed in the FAQ, please feel free to contact us using the inquiry form.
For FAQs regarding individual projects, please see the “Frequently Asked Questions” page.
Are you interested in our business?
Are you interested in our business?
Medical professionals, investors, and members of the press, please feel free to contact us by filling out the necessary information in the email form. Our representatives will get back to you promptly.
Medical professionals, investors, and members of the press, please feel free to contact us by filling out the necessary information in the email form. Our representatives will get back to you promptly.